Evaluating Autologous Stromal Vascular Fraction in Subjects With Vocal Fold Scar
Primary Purpose
Vocal Fold Scars
Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Autologous adipose derived SVF
Sponsored by

About this trial
This is an interventional treatment trial for Vocal Fold Scars
Eligibility Criteria
Inclusion Criteria:
- Signed informed consent
- Subject's age between 18 and 65-year-old
- Voice handicap index greater than 60/120
- Scarred vocal folds or congenital sulcus or after vocal fold surgery (Scarring will be scored during examination and identification of scarred vocal folds and hoarseness. This criterion includes the lack of or decreased mucosal wave of the vocal fold during videostroboscopy exam. Scoring of scar based on laryngoscopic exam: Type I: atrophy of lamina propria with/without affected epithelium. Type II: the epithelium, lamina propria, and muscle are affected. Type III: scar located on the anterior commissure. Type IV: this category includes extended scar formation in both anteroposterior and rostro-caudal axis, with significant loss of vocal fold mass)
- Unilateral or Bilateral vocal fold scarring
- At least 1-year delay after initial surgery
- Negative pregnancy test and contraception for woman of childbearing age. Women of childbearing age must use contraception at least 4 months pre and post SVF administration.
Exclusion Criteria:
- Refusal of speech therapy
- History of malignant lesion or severe dysplasia of the scarred vocal fold
- Contraindication to anesthesia, anticoagulant treatment, coagulation disorders, active infectious disease
- Refusal or inability to comply with study procedures
- Pregnant and lactating woman
Major chronic medical condition that could affect treatment or quality of SVF product. These include:
- Current treatment or within 6 months of last treatment for cancer.
- Blindness
- Known history of Chronic Obstructive Pulmonary Disease
- Known history of Coronary Artery Disease or Myocardial Infarction
- Known history of Dementia,
- Known history of Kidney Disease
- Known history of Cerebral Vascular Accident or Stroke
- Abnormal screening lab. If the laboratory reports a single, non-clinically relevant, non-life-threatening result for any of these studies and is the only excluding factor it may be repeated 1 week later if the subject wishes. Normalization of that laboratory study will then be considered non-exclusionary.
- Post-Radiation scarring of vocal folds.
Sites / Locations
- Mayo Clinic in Arizona
- Mayo Clinic FloridaRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
SVF for treating scarred vocal folds
Arm Description
Subject identified with scarred vocal folds will have autologous adipose derived SVF harvested and applied to scarred vocal folds.
Outcomes
Primary Outcome Measures
Adverse events post SVF administration
Number of adverse events related to SVF via endoscopy into vocal folds defined as inflammation or swelling indicated by red or swollen vocal folds or evidence of a hemorrhage indicated by a bleed at or near the site of delivery. This will be evaluated during stroboscope exam.
Secondary Outcome Measures
Voice handicap Index
Change in the self-reported voice handicap index to describe voices and effects of voices on subject lives, measure using a total score range from 0-120; 0-30=mild, 31-60=moderate, 60-120=severe
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05354544
Brief Title
Evaluating Autologous Stromal Vascular Fraction in Subjects With Vocal Fold Scar
Official Title
A Pilot Study Evaluating the Safety and Feasibility of Autologous Stromal Vascular Fraction in Subjects With Vocal Fold Scar
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 2023 (Anticipated)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Shane A. Shapiro
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this research study is to assess if autologous Stromal Vascular Fraction (SVF) taken from the stomach or hips can help heal vocal fold scars.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vocal Fold Scars
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
SVF for treating scarred vocal folds
Arm Type
Experimental
Arm Description
Subject identified with scarred vocal folds will have autologous adipose derived SVF harvested and applied to scarred vocal folds.
Intervention Type
Biological
Intervention Name(s)
Autologous adipose derived SVF
Intervention Description
A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.
Primary Outcome Measure Information:
Title
Adverse events post SVF administration
Description
Number of adverse events related to SVF via endoscopy into vocal folds defined as inflammation or swelling indicated by red or swollen vocal folds or evidence of a hemorrhage indicated by a bleed at or near the site of delivery. This will be evaluated during stroboscope exam.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Voice handicap Index
Description
Change in the self-reported voice handicap index to describe voices and effects of voices on subject lives, measure using a total score range from 0-120; 0-30=mild, 31-60=moderate, 60-120=severe
Time Frame
Baseline, Week 1, and Months 1, 3, 6, 9, 12, and 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed informed consent
Subject's age between 18 and 65-year-old
Voice handicap index greater than 60/120
Scarred vocal folds or congenital sulcus or after vocal fold surgery (Scarring will be scored during examination and identification of scarred vocal folds and hoarseness. This criterion includes the lack of or decreased mucosal wave of the vocal fold during videostroboscopy exam. Scoring of scar based on laryngoscopic exam: Type I: atrophy of lamina propria with/without affected epithelium. Type II: the epithelium, lamina propria, and muscle are affected. Type III: scar located on the anterior commissure. Type IV: this category includes extended scar formation in both anteroposterior and rostro-caudal axis, with significant loss of vocal fold mass)
Unilateral or Bilateral vocal fold scarring
At least 1-year delay after initial surgery
Negative pregnancy test and contraception for woman of childbearing age. Women of childbearing age must use contraception at least 4 months pre and post SVF administration.
Exclusion Criteria:
Refusal of speech therapy
History of malignant lesion or severe dysplasia of the scarred vocal fold
Contraindication to anesthesia, anticoagulant treatment, coagulation disorders, active infectious disease
Refusal or inability to comply with study procedures
Pregnant and lactating woman
Major chronic medical condition that could affect treatment or quality of SVF product. These include:
Current treatment or within 6 months of last treatment for cancer.
Blindness
Known history of Chronic Obstructive Pulmonary Disease
Known history of Coronary Artery Disease or Myocardial Infarction
Known history of Dementia,
Known history of Kidney Disease
Known history of Cerebral Vascular Accident or Stroke
Abnormal screening lab. If the laboratory reports a single, non-clinically relevant, non-life-threatening result for any of these studies and is the only excluding factor it may be repeated 1 week later if the subject wishes. Normalization of that laboratory study will then be considered non-exclusionary.
Post-Radiation scarring of vocal folds.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Reagan Dukes
Phone
904-953-5144
Email
dukes.reagan@mayo.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy Rutt, DO
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Arizona
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
58054
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Lott, MD
Facility Name
Mayo Clinic Florida
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Reagan Dukes
Phone
904-953-5144
Email
dukes.reagan@mayo.edu
12. IPD Sharing Statement
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials
Learn more about this trial
Evaluating Autologous Stromal Vascular Fraction in Subjects With Vocal Fold Scar
We'll reach out to this number within 24 hrs